Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is “science” enough to tackle the epidemic?

G. B. Migliori, R. Loddenkemper, F. Blasi, M. C. Raviglione
European Respiratory Journal 2007 29: 423-427; DOI: 10.1183/09031936.00001307
G. B. Migliori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Loddenkemper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Blasi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. C. Raviglione
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Fig. 1—
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1—

    Robert Koch (1843–1910), who discovered Mycobacterium tuberculosis in 1882. Nobel Laureate Physiology or Medicine, 1905.

  • Fig. 2—
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2—

    The title page of Robert Koch's original article published in Berliner Klinische Wochenschrift on April 10, 1882 1. This journal is no longer in existence. Provided courtesy of H.L. Rieder (Tuberculosis Division, International Union Against Tuberculosis and Lung Disease, Paris, France).

  • Fig. 3—
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3—

    The global prevalence of multidrug-resistant tuberculosis (MDR-TB) among new cases and the countries in which at least one case of extensively drug-resistant TB (XDR-TB) was described. MDR: cases resistant to at least rifampicin and isoniazid. XDR: resistance to at least rifampicin and isoniazid, in addition to any fluoroquinolone, and to at least one of the three following injectable drugs used in anti-TB treatment: capreomycin, kanamycin and amikacin. The following countries had at least one case of XDR-TB described: Argentina, Armenia, Bangaldesh, Brazil, Chile, Czech Republic, Ecuador, France (one case imported), Georgia, Germany, Italy, Republic of Korea, Latvia, Mexico, Peru, Portugal, Russian Federation, South Africa, Spain, Thailand, the UK and the USA. Figure reproduced from 4 with permission from the Stop TB Department, World Health Organization, Geneva, Switzerland.

PreviousNext
Back to top
View this article with LENS
Vol 29 Issue 3 Table of Contents
European Respiratory Journal: 29 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is “science” enough to tackle the epidemic?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is “science” enough to tackle the epidemic?
G. B. Migliori, R. Loddenkemper, F. Blasi, M. C. Raviglione
European Respiratory Journal Mar 2007, 29 (3) 423-427; DOI: 10.1183/09031936.00001307

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is “science” enough to tackle the epidemic?
G. B. Migliori, R. Loddenkemper, F. Blasi, M. C. Raviglione
European Respiratory Journal Mar 2007, 29 (3) 423-427; DOI: 10.1183/09031936.00001307
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • XDR-TB: DEFINITION
    • XDR-TB EPIDEMIOLOGY AND SPREAD
    • IMPLICATIONS AND CHALLENGES FOR TB CONTROL
    • PROPOSED SOLUTIONS FOR XDR-TB PREVENTION AND CONTROL
    • ROLE OF SCIENTIFIC SOCIETIES AND THE EUROPEAN RESPIRATORY SOCIETY IN THE PREVENTION AND CONTROL OF XDR IN EUROPE
    • CONCLUSIONS
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Commemorating World Tuberculosis Day 2022
  • Is low level of vitamin D a marker of poor health or its cause?
  • Risky political game with climate change
Show more Editorial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society